Sponsors (4)
Introduced March 17, 2026 by John F. Reed · Last progress March 17, 2026
The bill modestly increases and clarifies federal support for cell and cord blood transplantation—potentially improving transplant availability and program planning—while imposing a small ongoing federal cost and creating risks of added administrative burdens and possible unintended access limits if implementation or appropriations fall short.
Patients needing bone marrow, stem cell, or cord blood transplants will see increased program support because the C.W. Bill Young Cell Transplantation Program is authorized an additional $2,000,000 per year for FY2027–FY2031, improving access, coordination, and continuity of transplant services.
Hospitals, transplant centers, and blood banks may get clearer statutory authority and updated requirements for maintaining and accessing a national cord blood inventory, which can improve availability of cord blood units for transplants.
Researchers and cord blood banks could benefit from clarified duties, definitions, or processes that streamline cord blood collection, storage, matching, and related coordination activities.
Some patients could face reduced access if revised statutory language unintentionally narrows eligibility or access criteria for cord blood units or related transplant services.
Hospitals, cord blood banks, and HRSA may incur additional administrative and compliance costs to implement and meet any revised statutory requirements.
Taxpayers will fund an extra $2,000,000 per year during FY2027–FY2031, increasing federal outlays without explicit offsets in the bill.
Based on analysis of 3 sections of legislative text.
Extends and raises authorized annual funding for the C.W. Bill Young Cell Transplantation Program for FY2027–2031 and revises the law governing the program's cord blood inventory.
Extends federal authorization levels for the C.W. Bill Young Cell Transplantation Program by preserving the current $31,009,000 annual authorization and adding a $33,009,000 per-year authorization for fiscal years 2027–2031, and makes a substantive revision to the law governing the Program’s cord blood inventory. The bill changes the statutory text that directs how cord blood inventory functions are carried out under the Program; the exact text of that change was not provided, so the operational effects depend on the content of the substituted language.